Individualization of therapy using Mammaprint: from development to the MINDACT Trial

Area of Science:

• Oncology
• Genomics
• Translational Research

Background:

• Current breast cancer adjuvant chemotherapy decisions rely on conventional clinicopathological criteria, which are often inaccurate.
• Tumors with similar characteristics can exhibit vastly different patient outcomes, highlighting the need for improved prognostic tools.
• Accurate patient stratification is crucial for optimizing adjuvant chemotherapy selection and patient benefit.

Purpose of the Study:

• To review the development and validation of a 70-gene signature (Mammaprint) for predicting distant metastasis in early-stage breast cancer.
• To assess the utility of Mammaprint in identifying patients who may benefit most from adjuvant chemotherapy.
• To discuss the prospective validation of Mammaprint in the MINDACT clinical trial.

Main Methods:

• Development of a 70-gene expression profile using high-throughput microarray analysis.
• Retrospective validation and feasibility studies of the 70-gene signature.
• Prospective validation in the large-scale adjuvant MINDACT clinical trial (Microarray In Node-negative Disease may Avoid ChemoTherapy).

Main Results:

• The 70-gene signature (Mammaprint) was identified as an accurate predictor of distant metastasis in early-stage breast cancer.
• Retrospective and feasibility studies demonstrated the profile's potential for patient selection.
• Prospective validation in the MINDACT trial confirmed its clinical utility.

Conclusions:

• The 70-gene signature (Mammaprint) offers a more accurate method for selecting early-stage breast cancer patients for adjuvant chemotherapy.
• Genomic profiling can significantly improve treatment decisions compared to conventional criteria.
• Mammaprint has demonstrated its value in large clinical trials, supporting its role in personalized breast cancer treatment.